Compare FEIM & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | BNTC |
|---|---|---|
| Founded | 1961 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 396.3M |
| IPO Year | 1994 | 2020 |
| Metric | FEIM | BNTC |
|---|---|---|
| Price | $82.49 | $10.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $51.50 | $27.67 |
| AVG Volume (30 Days) | ★ 314.6K | 125.7K |
| Earning Date | 03-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $63,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.73 | N/A |
| P/E Ratio | $215.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.05 | $9.26 |
| 52 Week High | $89.76 | $16.76 |
| Indicator | FEIM | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 29.32 |
| Support Level | $44.48 | N/A |
| Resistance Level | $89.68 | $13.49 |
| Average True Range (ATR) | 4.67 | 0.73 |
| MACD | 0.75 | -0.22 |
| Stochastic Oscillator | 80.35 | 14.30 |
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.